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Cooperative groups, of which the RadiationTherapy Oncology Group is one example, con-
duct national clinical trials that often involve the use of radiation therapy. In preparation
for such a trial, the cooperative group prepares a protocol to define the goals of the trial,
the rationale for its design, and the details of the treatment procedure to be followed. The
Radiological Physics Center (RPC) is one of several quality assurance (QA) offices that is
charged with assuring that participating institutions deliver doses that are clinically con-
sistent and comparable. The RPC does this by conducting a variety of independent audits
and credentialing processes. The RPC has compiled data showing that credentialing can
help institutions comply with the requirements of a cooperative group clinical protocol.
Phantom irradiations have been demonstrated to exercise an institution’s procedures for
planning and delivering advanced external beam techniques (1–3). Similarly, RPC data indi-
cate that a rapid review of patient treatment records or planning procedures can improve
compliance with clinical trials (4). The experiences of the RPC are presented as examples
of the contributions that a national clinical trials QA center can make to cooperative group
trials. These experiences illustrate the critical need for comprehensive QA to assure that
clinical trials are successful and cost-effective. The RPC is supported by grants CA 10953
and CA 81647 from the National Cancer Institute, NIH, DHHS.
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INTRODUCTION
In recent years the approach to treating cancer patients with radi-
ation therapy has evolved considerably. In past decades, it was
common for clinicians to base treatment decisions on their indi-
vidual past experiences, but today it is more common to employ
“evidence-based medicine” and derive prescriptions from data
obtained through clinical trials (5). The highest-level evidence
for any type of therapy originates from systematic reviews of
randomized clinical trials.
This article will review the clinical trials programs in the US
and elsewhere, and will discuss requirements for quality assurance
(QA) procedures specific to participation in these multi-center
clinical trials. For related information, the reader is referred to
previous publications on the topic (6, 7).
CLINICAL TRIALS
According to data from the Radiological Physics Center (RPC),
nearly 70% of all US radiation therapy centers participate to
some degree in cooperative group clinical trials (8). About 25%
of the centers collectively enroll more than 1,000 patients per
year on protocols managed by one or more of the clinical trials
groups. For a treatment center to join and continue member-
ship in the cooperative groups, the institution’s physics staff must
perform specific QA procedures. For protocols that require or per-
mit radiation therapy, there are particular radiation therapy QA
and data submission requirements for each patient entered into
the trial. Participation in certain advanced technology protocols
such as those requiring three-dimensional (3-D) conformal treat-
ment, intensity-modulated radiation therapy (IMRT), volumetric
modulated arc therapy (VMAT), stereotactic radiation therapy, or
brachytherapy require a substantial physics effort to qualify the
institution to enter patients. Further physics effort often is nec-
essary to submit the required data for each patient treated under
protocol.
A clinical trial typically compares a new treatment, or new
treatment approach, with the “standard treatment.” In the case
of radiation therapy, the standard treatment typically is defined
as the most-commonly delivered dose prescription using the
most-popular treatment approach.
Clinical trials are classified as Phase I, II, or III to describe the
goals of the trial and the level of evaluation that is being performed.
Phase I trials generally recruit small numbers of patients and may
determine the dose that can be tolerated, the delivery method,
or perhaps a novel fractionation procedure. Patients recruited to
Phase I trials may be chosen from a select group such as those not
expected to respond well to conventional treatments. If the Phase
I trial is successful, a Phase II trial will follow and may recruit a
larger number of patients. The results from a Phase II study will
provide a measure of the effectiveness of the new treatment in
a group of patients where it is thought the new treatment may
be superior in outcome to the standard treatment. This can help
determine the sample size required for a definitive trial by provid-
ing an estimate of the variability in response, an estimate of the
difference in response expected between the new treatment and
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the conventional treatment, and identification of sub-populations
that respond differently to the larger patient group. It may take
many years to complete Phase I and II trials; on occasion these
trials are combined.
A trial that randomizes patients between two (or more) arms
comparing a new treatment against a standard treatment is called
a Phase III trial. Phase III trials usually follow smaller Phase I
and II trials that test the safety and effectiveness of the new treat-
ment approach. Phase III trials randomize patients to the arms
of the study to avoid a systematic difference (or bias) between
the groups due to factors other than the new treatment approach.
Patients may be further sub-divided, or stratified, if there are other
known factors that may influence the patient outcome, such as
smoking history. Stratification may reduce the possibility of a trial
reporting a null hypothesis (i.e., there is no difference between
treatments) when in fact there is a difference (9). Stratification may
also be useful for pooling data with other clinical trials to conduct
meta-analyses. A single clinical trial may be powered sufficiently to
answer only the primary trial question but when multiple studies
are combined, there opens the possibility of generating conclusive
results for sub-studies and secondary trial questions (10).
A multi-institutional Phase III clinical trial has the potential to
set a new standard for clinical management of cancer patients, and
the results of such research could therefore be implemented widely.
For the results of a clinical trial to be replicated on a national scale,
the clinical trial must clearly define the treatment parameters used.
In the case of trials involving radiation oncology there are two
general approaches:
• When the radiation therapy is not part of the trial question, e.g.,
in the testing of a new drug, centers are instructed to deliver the
radiation therapy using their “standard” approach, even though
this might be quite different among centers. Should such a trial
be successful it can then be concluded that the study drug will (or
will not) result in a superior outcome regardless of the radiation
therapy technique.
• A second approach is to define in precise detail how the radio-
therapy treatment will be delivered. A strict QA program is
necessary to confirm that the dose was delivered according to the
protocol. This approach is required for trials that include a ques-
tion related to the radiotherapy treatment and is becoming more
common as potentially a smaller number of patients are required
for any trial (11), and hence statistically significant results can
be achieved in a shorter data collection time. A demanding QA
program is particularly relevant when the expected difference
between the arms of the trial is expected to be small.
RADIATION THERAPY TECHNIQUE
The Section “Radiation Therapy Technique” of a trial protocol
must provide sufficient detail for planning and treatment delivery
to be consistent across participating centers. The level of detail
may vary widely across trials depending on many factors relat-
ing to the relevance of the radiotherapy treatment to the question
the trial aims to answer. Using the example described above, a
trial investigating the use of a new drug to delay the onset of dis-
ease progression may state only the minimum dose that should be
delivered to the PTV and each participating center may then follow
their own in-house treatment protocol. A trial comparing a high
dose hypofractionated treatment to the lung using non-coplanar,
motion compensated fields against a standard treatment schedule
using conventional coplanar fields without motion compensation
requires a large degree of detail so that the distinction between the
two radiotherapy techniques is clear; so that patients do not come
to harm due to lack of understanding of the trial protocol, and
because the investigational arm may involve centers developing
many new techniques to comply with the protocol, each carrying
their own risk of misinterpretation due to limited experience.
An example of the contents of the Section “Radiation Therapy
Technique” of a trial protocol is shown in Table 1. The Section
“Radiation Therapy Technique” should start by stating the plan-
ning objectives (e.g., radical or palliative intent), treatment modal-
ities allowed, dose prescription (including details of how and
where the dose should be prescribed) and the treatment schedule,
including dose per fraction and overall treatment time. Although
specifying dose prescription may sound simple, some thought
should be put into how the prescription may be interpreted for
different planning techniques. For example a trial permitting only
conformal radiotherapy using photons may choose to use the rec-
ommendations of ICRU 50 and 62 (12, 13) with a prescription
based on a point within the center of the treatment volume. A trial
that allows only an IMRT approach may use the recommendations
of ICRU 83 (14) with dose prescription based on a median dose
and a number of planning objectives. Great care must be taken
in defining the method of dose prescribing, as the outcome from
plans that are produced by the participating centers may vary suffi-
ciently that trial results cannot be interpreted (15, 16). As a general
recommendation, the principal investigator (PI) must specify the
treatment planning objectives and provide details on how these
objectives may be realized with the various treatment planning
techniques permitted. For example, a trial that is investigating the
influence on tumor control of the timing of radiotherapy relative
to surgery may permit 3DCRT and IMRT, with the purpose of
IMRT in this scenario to reduce side effects of treatment. As the
study endpoint is tumor control due to the timing of surgery, it
would not be appropriate in this trial to use IMRT to boost target
sub-volumes and hence, in this example the planning objectives
would be to deliver a uniform equivalent dose to the treatment
volume regardless of treatment planning technique. This may be
Table 1 | Example of the table of contents for the Section “Radiation
TherapyTechnique” of a clinical trial.
6.0 Radiation therapy
6.1 Dose specification
6.2 Technical factors
6.3 Localization, simulation, and immobilization
6.4 Treatment planning/target volumes
6.5 Clinical structures
6.6 Documentation requirements
6.7 Compliance criteria
6.8 Radiation therapy quality assurance review
6.9 Radiation therapy adverse events
6.10 Radiation therapy adverse events reporting
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achieved through specifying the maximum and minimum dose
that would be common to 3DCRT and IMRT techniques. The
prescribed dose, however, must be chosen so that it is interpreted
equivalently by either technique. For example, the same dose value
may be prescribed to the ICRU 50 point for the 3DCRT plans and
to the median PTV dose for IMRT plans (14, 15). Consequently,
dose-volume histograms are often used prospectively to define the
intended dose to the target and organs at risk.
Details to be provided in the treatment planning section are
to be described in a forthcoming report from AAPM Task Group
113. The trial protocol should, for example, state that calcula-
tions should be carried out with a heterogeneity correction (where
appropriate) and in some cases it may be necessary to specify
particular algorithms that may (or may not) be used in a trial.
For example, trials involving highly conformal treatment deliv-
ery to the thoracic region may insist that the TPS shall utilize
a 3D dose calculation algorithm capable of performing calcula-
tions which account for variations in lateral scatter in the presence
of 3D computed tomography (CT)-defined heterogeneities. Pen-
cil beam algorithms for example, may be excluded for such trials
because their performance is known to be inferior in the presence
of low-density heterogeneities (17).
Clinical structure definitions may be related to published data
relating the dose-planning constraints to clinical toxicities. For
example, the QUANTEC papers (18) provide evidence for the dose
response in a number of critical organs.
The Documentation Requirements section of the clinical trial
protocol (see Table 1) should provide details of the data that shall
be submitted for review. Data generally are submitted in electronic
format and must be anonymized prior to submission. The data
selected for review must be sufficient to confirm that the center
has created a treatment plan that conforms to the trial protocol.
In most cases, the treatment plan will be submitted in a common
format such as DICOM-RT (19) that can read by the coopera-
tive clinical trials group (CCTG) plan review software. In addition
the trial may require verification images be submitted along with
an end of treatment report to confirm the patient was treated
as planned. Additional data may be requested to support future
analyses appropriate to the trial end points.
ROLE OF MEDICAL PHYSICS IN CLINICAL TRIALS
Multi-center clinical trials operated through CCTGs such as the
Radiation Therapy Oncology Group (RTOG), European Organi-
zation for Research and Treatment of Cancer Radiation Oncology
Group (EORTC-ROG), Trans-Tasman Radiation Oncology Group
(TROG), etc., generally have the greatest impact on changing clin-
ical practice as these groups set high standards for trial design,
QA, and management, resulting in high quality data to support
trial results that can be reproduced in the clinic. Although the
process of developing a clinical trial may vary among the groups,
the same general principles apply which in turn provides an oppor-
tunity for clinical trial groups to collaborate to increase patient
recruitment.
A clinical trial typically starts as a small pilot study (which may
be conducted in a single center or a small number of centers) or
a Phase I and/or II trial to confirm the new treatment is worthy
of further investigation. The PIs will be invited by the CCTG to
put forward their ideas at the group’s research strategy commit-
tee meeting where they can be subject to peer review. Typically
peer review will involve a multi-disciplinary audience and usually
includes a consumer representative, statisticians, and experienced
trial investigators. Following peer review and general agreement
from members of the CCTG, the investigator will carry out a
feasibility survey to confirm that sufficient numbers of patients
can be recruited in a reasonable time frame. At this stage the PI
will confirm details of the “standard treatment” and the ability of
centers to offer the investigational treatment. Once the feasibility
is confirmed, protocol writing and applications for funding can
begin.
In writing a protocol, each contributing author is required to
follow the standard format relevant to the particular CCTG. Addi-
tional sections can be added as required for a particular trial. It
would be expected that a medical physicist, or a team of physicists,
be involved in the writing of the technical sections of the protocol,
including the QA section. This highlights one of the most impor-
tant roles of the medical physicist in clinical trial involvement. A
large responsibility lies with the medical physicist in identifying
the level of detail that needs to be included in the protocol and
providing instructions that, when appropriate, are not hardware
specific and can be followed in the multi-vendor environment
commonly associated with CCTG multi-institutional trials.
A medical physicist who has an understanding of the needs
of a clinical trial will be able to identify key risk areas that could
adversely affect the success of the trial. For example, a physicist
can define the variability in the way a particular cancer might
be treated, such as cancers in the thoracic region where a variety
of techniques for managing tumor motion may lead to a range
of outcomes, even if all sites apply the same treatment margins.
The medical physicist may play a key role in defining the need
for a QA program by defining the risks associated with predicted
intercenter variability in treatment delivery (20) and also provide
an estimate of the cost for executing the QA program which is
required at the time of applying for grants to manage the clinical
trial. In addition, the medical physicist may play a role in the risk
management process associated with the trial such as by providing
guidance on estimating radiation doses due to supplemental imag-
ing techniques. This may vary based on the techniques or vendor
specific equipment used. Cone beam CT (CBCT) is a good exam-
ple where local ethics committees may not approve daily imaging
unless good justification for the additional dose can be provided.
These key points should be discussed in detail with the trial investi-
gator early in the development of the trial protocol and well before
applications for trial funding are made.
Most CCTGs now recognize the need to include a physicist in
the trial management committee and in most cases, such a role will
be recognized in the author list when the trial results are published.
In addition, a medical physicist may act in an advisory role to the
CCTG. Prior to opening to patient recruitment, all CCTGs require
trial protocols to be approved by a multi-disciplinary committee
to ensure that the protocol meets the high standards expected of
the trial group. Such committees contain technical representatives,
including medical physicists who are typically practicing clini-
cal medical physicists, or physicists that have substantial clinical
medical physics experience.
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Hospital participation in clinical trials varies; however, it has
been shown that patients treated at hospitals that contribute larger
numbers of patients to trials do better than those with low con-
tribution rates (21). The clinical medical physicist involvement
in clinical trial work may therefore vary, but the importance of
this work cannot be understated as the outcome of a clinical trial
may affect the way many patients, locally, nationally, and on the
international scale, are treated. If asked to assist with clinical trial
participation, the medical physicist should attempt to understand
the goals of the clinical trial and if necessary, contact the trial
physicist or appropriate QA office to confirm the requirements
of the trial. The local medical physicist should also carefully read
the Radiotherapy and QA sections of the protocol and the require-
ments for data submission. In some situations additional resources
may be required and this should be identified early. Some trials
may require modifications to the protocols used locally for patient
treatment and ideally a member of staff should be allocated the
task of identifying the special needs of a trial to minimize the risk
of protocol violations. Investing time in identify the needs of a trial
and setting up processes to comply with the protocol early will save
time in the long run by avoiding the need to re-submit data.
DEVELOPMENT OF A QUALITY ASSURANCE PROGRAM
In the context of a clinical trial, QA involves many different dis-
ciplines and a range of tasks including verification of patient
eligibility to enter the trial, assurance that all tests and tumor
response/toxicity measures are carried out at the time intervals
specified in the protocol, verification that data entered into case
report forms (CRFs) are accurate and have been entered into the
trial database correctly and, finally, assurance that the treatment
was delivered according to the trial protocol. In brief, the role of
a QA program within a clinical trial can be simply defined as a
program to minimize the possibility of systematic discrepancies
in treatment management among participating institutions. The
specific role of a clinical trials QA program has been described by
van Tienhoven et al. who wrote that a trial-specific QA program
should include procedures that can be conducted readily, should
be able to identify and quantify variations in relevant parameters,
should be able to detect and correct significant variations, and
should be able to demonstrate an effect on the outcome of the
trial (22).
The importance of a good quality control program within a
clinical trial has been demonstrated on many occasions (23–25).
Pettersen et al. demonstrated the effect on sample size required
for a clinical trial in the presence of dose uncertainties, and in
turn, Bentzen et al. described the potential clinical effects of these
uncertainties (11, 20). Ohri et al. reported a meta-analysis of
several trials and demonstrated that in most cases there were
correlations between the quality of radiation treatment delivery
and patient outcome (26). Fairchild et al. similarly reported a lit-
erature review of 17 multicenter clinical trials demonstrating a
correlation between radiation therapy quality and trial outcome
(27). Insufficient QA in clinical trials, as well as QA that is per-
formed after accrual to the trial has concluded, also have been
found to degrade the outcome of a clinical trial. In a clinical trial
investigating the use of a hypoxic cytotoxin agent in the treat-
ment of head-and-neck cancers, the impact of non-conformance
to the trial protocol was found to be larger than the impact of the
trial drug with the data from the non-protocol compliant treat-
ment plans potentially detracting from the ability of the trial to
demonstrate the benefits of the drug (21, 28).
The topic of QA in clinical trials is well covered in the forthcom-
ing AAPM publication from Task Group 113. In addition, AAPM
Report 86 (7) provides an overview of QA in clinical trials with a
focus on the role of various QA groups within the National Cancer
Institute in Northern America. Purdy (29) also provides details of
the US and European clinical trial programs.
The effort required to conduct a comprehensive QA program
has been documented thoroughly. Pawlicki et al. (30) have pro-
posed a risk-based approach to QA similar to those used in
industry. The principle to be followed states that the frequency
and intensity of verifying a specific function or activity should
increase when: (a) the probability that something will go wrong
is increased, (b) the degree of damage (e.g., incorrect treatment,
treatment of incorrect patient, etc.) that can be caused is increased,
or (c) the likelihood that a failure could escape detection is
increased. It must be understood that patient safety remains the
responsibility of the local hospital, and not the clinical trials group.
The role of a clinical trial QA program is therefore not to spec-
ify what and how often a particular component should be tested,
except to confirm that the local QA program meets national stan-
dards. Instead the clinical trial QA program will use a risk-based
approach to identify what aspects of the treatment delivery chain
are likely to affect the ability to answer the trial question. The QA
program must be able to operate within a reasonable budget, have
access to appropriately qualified personnel with adequate experi-
ence in the appropriate field, not place too great a burden on the
treating center so that it prohibits their participation, and set tol-
erance limits that are appropriate for the accuracy required within
the specific trial. The latter point is the most challenging aspect of
a clinical trial QA program. NCI and EORTC radiation therapy tri-
als now require centers to participate in regular external dosimetry
audits, but in addition to this, most QA programs also require the
clinical trial center to demonstrate they have achieved a defined
level of accuracy using their in-house equipment for other aspects
of the treatment delivery chain.
In addition to treatment delivery accuracy, the QA program
must be designed to confirm that all aspects of the protocol were
followed. The process for achieving this and the frequency of
monitoring protocol compliance varies between trials and is again
related to resources and risk. In the ideal world, all treatment plans
for all trials would be reviewed prior to patients starting treatment.
This is indeed necessary for trials where protocol non-compliance
is likely and such non-compliance is likely to impact on the trial
outcome. In such situations, it is necessary to support the trial
with a team of appropriately qualified reviewers. These reviewers
may need to develop plan review consensus guidelines to ensure
consistency.
Prior to entering patients into a clinical trial, centers may be
required to complete a credentialing program. Details of creden-
tialing programs are discussed later. The advantage of a credential-
ing program is that centers have the opportunity to demonstrate
they have read, understood and are able to follow the trial pro-
tocol, and that they are able to submit data to the clinical trials
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center for review. It also provides the PI with an insight into the
likely frequency of protocol violations, identifies ambiguities in
the protocol, and assists centers to achieve the objectives of the
trial protocol. Some aspects of credentialing can be completed in
advance, which can enable centers to be prepared by the time a
trial opens.
In addition to credentialing a treating center for clinical trial
participation, the basic QA program for most clinical trials involv-
ing radiotherapy will require the center to submit a minimum
number of treatment plans for review. Clinical trials that per-
mit complex or novel techniques, or require a specific level of
treatment delivery accuracy may also incorporate specific QA pro-
grams. For example, to use IMRT techniques in an RTOG trial,
centers must successfully complete the IMRT phantom exercise
(31). Further tests may be required for specific trials. Similar QA
programs exist for trials involving IMRT with intrathoracic lesions,
image-guided radiation therapy (IGRT), and brachytherapy.
CREDENTIALING FOR RADIATION THERAPY CLINICAL TRIALS
A clinical trial may incorporate a credentialing program in an
effort to minimize the number of protocol violations and improve
the overall quality of the trial (32). Credentialing offers the oppor-
tunity to confirm investigators have read and understood the trial
protocol and have the necessary resources to treat the patients in
all arms of the trial in accordance with the trial’s specifications.
When trials allow the introduction of a new technique, creden-
tialing is also an opportunity to provide education, peer review,
and an external formal assessment that the new technique has
been appropriately commissioned prior to clinical implementa-
tion. For example, the UK trial PARSPORT allowed many centers
to implement IMRT for head-and-neck cancers as a result of par-
ticipation in the trial (33). Human error has been identified as
one of the major contributing factors in patient treatments and
therefore some clinical trial groups will require process maps to be
developed and submitted for approval prior to a center opening a
clinical trial (34).
Credentialing studies may be costly to execute and are often
seen as an additional burden in the busy clinic, as it is perceived
that no patient will benefit from the exercise. A good credentialing
program however, will identify and correct trial protocol ambi-
guities, provide education to the staff and potentially limit the
number of treatment plans that must be re-submitted due to pro-
tocol violations. The credentialing program will also encourage
improvements in treatment delivery that will affect all patients
treated at the center, not just those treated on clinical trials.
TRIAL-SPECIFIC CREDENTIALING
Pre-trial credentialing may require centers to demonstrate that
they are able to achieve a high level of treatment accuracy which
may be an important element in dose escalation studies (35) or
studies involving tight treatment margins or hypofractionated
schedule (36).
Clinical trials that require the use of advanced technologies such
as IMRT and prostate brachytherapy are considered sufficiently
challenging that institutions are required to demonstrate their
ability to use these technologies before being permitted to register
patients (37–39). The RPC participates in the credentialing process
for a number of clinical trials through several NCI-funded coop-
erative groups. In most cases, the RPC collaborates with one or
more of several other NCI-funded QA offices, and has on occasion
collaborated with international QA offices.
Credentialing for such clinical trials generally involves an
evaluation of most if not all of the following aspects:
• Attestation to use of the particular advanced technology to treat
patients previously: institutions must demonstrate that they are
familiar with the technique and have used it to treat at least some
minimum number of patients.
• Facility questionnaire: this questionnaire asks institutions to
describe relevant aspects of their treatment planning and
delivery equipment, their QA procedures, and in some cases,
the personnel who will be participating in protocol patient
treatments.
• Knowledge assessment questionnaire: the physician is asked to
take a simple quiz to indicate that he or she is familiar with the
protocol and its requirements.
• Benchmark case or phantom: for the more complex technolo-
gies, the institution may be required to submit a treatment plan
generated for a standardized geometry or CT data set (a“dummy
run”), or simulate, plan, and treat a geometric or anthropomor-
phic phantom (an “end-to-end test”). If the protocol requires
a benchmark treatment plan, some QA offices such as the RPC
review the institution’s plan and re-calculate the doses at key
locations to evaluate the accuracy of the planning system. This
calculation is possible because the RPC has either measured data
collected through visits to the institution, or is able to use the
“standard data” described earlier (40). When anthropomorphic
phantoms are used, the delivered dose must be compared with
the institution’s plan to determine the agreement (1–3, 41–43).
An audit of institutions participating in trials run by the TROG
was reported by Kron et al. (38). A review of the RPC results was
recently reported by Molineu et al. describing more than 1,100
irradiations of a head-and-neck phantom (3).
• Patient-specific plan QA review: as part of credentialing, some
trials may require the treating site to also submit their standard
in-house dosimetry QA report for the plan created for the treat-
ment planning exercise, for example in the case of IMRT plans.
The QA report along with the in-house QA protocol may need to
be approved prior to trial activation. In this case the trial medical
physicist may be required to assess the suitability of the equip-
ment used by the trial center to perform the QA, the tolerance
limits defined in the in-house protocol and the experience of the
physics staff in carrying out the QA tasks.
• Electronic data submission: many clinical trials groups require
institutions to submit the treatment plans for protocol patients
digitally. Several QA offices can receive data electronically, and
the Image-guided Therapy QA Center (ITC) was established to
assist QA offices and study groups in this regard. The plans per-
formed for irradiation of the anthropomorphic phantoms also
must be submitted digitally to facilitate comparison with the
institutions’ own treatment plans.
• Quality assurance and dosimetry review: some QA offices,
including the RPC, review QA and dosimetry procedures,
and records from the participating institutions, to ascertain
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compliance with published recommendations such as those
from the AAPM (44, 45).
• Clinical review by radiation oncologist: in some cases, the proto-
col requires that the institution submit representative treatment
plans performed for patients treated previously using the tech-
nology being tested by the protocol, and techniques at least
similar to those required by the protocol. The plans are reviewed
by the study chair or a radiation oncologist to ensure that they
conform to the intentions of the study chair or his/her designee.
• Reviews of patient treatment records: in some cases, a QA
office will review the treatment plans prepared by participat-
ing institutions for patients registered on a clinical trial. When
the protocol is complex and treatment delivery errors could
mask the results of the trial, the study chair may require that
institutions submit their treatment plans for review before the
patients are treated. Such “rapid reviews” ensure that the treat-
ment plans meet the dosimetric requirements of the protocol.
An example of a recent protocol that requires rapid reviews is the
joint NSABP B-39/RTOG 0413 trial of accelerated partial-breast
irradiation (46).
EXTERNAL DOSIMETRY AUDITS
REMOTE AUDITS OF TREATMENT MACHINE OUTPUT
At least five organizations conduct regular independent audits of
treatment machine output calibration with mailed dosimeters.
They include the RPC based in Houston, TX, USA; Radiation
Dosimetry Services, also located in Houston; the International
Atomic Energy Agency (IAEA) based in Vienna; the European
Quality Assurance Laboratory/European Society for Therapeutic
Radiology and Oncology (EQUAL-ESTRO) located in Paris; and
the Section of Outreach Radiation Oncology and Physics at the
National Cancer Center of Japan, in Tokyo. Of these five centers,
the RPC has the largest program and monitors all of the institu-
tions (>1,800 institutions as of early 2012) that participate in NCI
sponsored clinical trials, both within the USA and internationally
(1, 32). The RPC initiated its TLD program for photon beams in
1977 (47, 48). In 1982 electron beams were included, and in 2007,
measurements of proton beams were initiated. In 2010, the RPC
adopted the use of optically stimulated luminescence dosimeters
(OSLDs) and largely discontinued the use of TLDs for photons
and electrons (49).
Most external audit systems are relatively simple; the RPC’s
system is an example. Each year, institutions receive a package
containing a lightweight platform and acrylic mini-phantoms con-
taining several OSLD “nanoDots” (Landauer, Inc., Glenwood, IL,
USA) for irradiation with each radiation beam. Instructions are
enclosed that explain the irradiation procedure and ask the institu-
tion to describe their calibration procedure. The blocks and other
equipment are returned to the RPC where the OSLDs are analyzed.
The RPC applies corrections for the differences in scatter between
the institution’s calibration conditions and the OSLD irradiation,
and for fading, dose linearity, and energy dependence of the OSLD
system (47).
The uncertainty of the OSLD system to measure output
of accelerators remotely has been evaluated and found to be
1.5% (50). This uncertainty is expressed as the standard devi-
ation of measurements of dose with the RPC’s OSLD system.
Consequently, the RPC’s measurement of an institution’s output
can be stated at an uncertainty of <5% using a 99% confidence
interval. The RPC has established ±5% as a threshold for accept-
ability. When the OSLD measurement disagrees with an institu-
tion’s stated dose by more than 5%, the RPC initiates a series of
activities to resolve the discrepancy. If the discrepancy cannot be
resolved through telephone calls and the review of procedures and
documentation, an on-site dosimetry visit is scheduled.
Audits of machine calibration have been described by several
other investigators. For example, Rassiah et al. described an inde-
pendent audit of treatment centers in Malaysia using TLDs (51).
Williams et al. described the early experience of the Australian
dosimetry audits using TLDs and OSLDs (23). Similarly, Mizuno
et al. described an audit system using rods made of a thermolu-
minescent glass (52). Their study demonstrated that the system
was suitable for measurements of treatment machine output, and
is proposed for use at a number of treatment centers in Japan. A
similar analysis in Korea led to the same conclusion (53). How-
ever, the experience at the IAEA in Vienna is comparable to that
of the RPC in terms of numbers of separate institutions audited,
although the frequency of audits is lower (54).
RESULTS OF REMOTE AUDITS OF MACHINE CALIBRATION
The RPC has described results from a large series of annual cal-
ibration audits (8, 55). Consistently each year, 5–6% of the US
megavoltage beams audited with TLD have fallen outside of the
RPC’s ±5% dose or 5 mm electron depth dose criteria on the
first measurement. The analysis indicated that the incorrectly cal-
ibrated beams are distributed among approximately 10–20% of
the institutions monitored by the RPC (Figure 1). This observa-
tion has been confirmed by on-site visit measurements using ion
chambers; among institutions visited by the RPC, approximately
10–15% had one or more beams outside of the RPC’s criteria on
an annual basis that required an investigation by the RPC (8, 55).
The precedent for performing the TLD audit annually was
established by the RPC many years ago and all current trial data
and results are based on having this level of QA. A review of EORTC
trial results indicated that decreases in tumor control probabil-
ity were associated with discrepancies in the beam calibration,
FIGURE 1 |The percent of institutions irradiatingTLD in any year that
had at least one beam that failed the RPC’s 5%/5 mm criteria for
acceptability.
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as measured by a TLD audit program (20). At the same time,
increases in normal tissue morbidity were associated with dis-
crepant high TLD measurements. The article also indicated that
sequential TLD audits improved the uniformity of the clinical
outcome and that small deviations in beam output might lead
to clinically important variations in outcome. Mailed TLD audits
were deemed to be an integral part of QA for trials. Other stud-
ies have shown the importance of independent audits to assure
clinical trial quality (11, 21).
The RPC data also showed that 41% of the institutions mon-
itored by the RPC had exactly one discrepancy detected by the
TLD program during the 10-years between 1998 and 2008 (55,
56). However, thanks at least in part to the RPC’s intervention, a
much smaller percentage had two or more discrepancies during
this period. As was indicated above, while calibration discrep-
ancies were detected for 15–20% of the major contributors to
clinical trials in any 1 year, these institutions did not consistently
have such discrepancies. Instead, significant calibration errors
apparently can occur at any institution at any time. Approxi-
mately 230 new machines are installed each year at institutions
participating in US NCI-funded clinical trials. New machines are
subject to calibration errors as they are put into clinical service,
with potentially serious results. These errors can occur as a result
of changes in procedures, the recruiting of inexperienced per-
sonnel, and frequently, with the installation of new treatment
equipment.
ON-SITE DOSIMETRY REVIEW VISITS
A dosimetry review audit has been recommended by several
organizations, including the AAPM and the IAEA (57, 58). An
independent on-site audit is especially important for solo practi-
tioners but is a valuable exercise for all practicing clinical med-
ical physicists. It need not be extensive, but should address key
activities such as basic calibrations, the overall QA program and
documentation.
A independent dosimetry review visit consists of a review of
the institution’s QA procedures and documentation; a review of
treatment records to ascertain the consistency of the procedures
used for treatment planning and monitor unit calculations; and
measurements of the radiation beams and radioactive sources. The
measurements should include mechanical alignment and accuracy
of position readout devices, light versus radiation field congru-
ency, calibration of treatment machine output and brachytherapy
source strength, relative field-size dependence, percent depth dose,
off-axis ratio, asymmetric jaw and irregular field parameters, and
accessory transmission factors. Additional measurements should
evaluate the basic data required for delivery of IMRT, including
small-field output factors, and the performance of a multi-leaf
collimator (MLC). A straight-forward spot-check of IGRT can be
performed with a simple phantom (36). Because of interest in
treating protocol patients with protons, the RPC and other QA
groups have developed and implemented procedures for visits to
proton-beam facilities (59).
The RPC has conducted on-site audits during its 45-year his-
tory, and has accumulated extensive measured data from several
thousand photon beams which have been grouped into 96 com-
binations of manufacturer, model, and beam energy (40). This
database of “Standard Data” enables the RPC to provide assistance
by comparing an institution’s measured data with the Standard
Data. Differences often point to measurement errors and help
identify the source of calibration errors detected by a mailed
audit.
MEASUREMENTS OF BEAM PARAMETERS DURING DOSIMETRY
REVIEW VISITS
During a dosimetry review visit, a QA office can evaluate many
aspects of performance of the institution’s dosimetry system. In
the RPC’s case, a report is prepared that indicates measurements
that disagree with the institution’s treatment planning dosimetry
data, and when the disagreements exceed appropriate thresh-
olds, the report includes recommendations to the institution for
improvement. These recommendations then demonstrate areas
that require attention by the institution. When considered in
aggregate, these recommendations form an indication of the areas
of general concern at the visited institutions. The common rec-
ommendations and the frequency with which institutions receive
them are shown in Table 2 (8). The recommendations indicated
by asterisks are considered important dosimetry parameters. On
average, 70% of visited institutions received one or more of these
recommendations.
REVIEWS OF QA PROGRAMS
Recommendations for performing routine QA in radiation ther-
apy departments are presently in flux. The only widely accepted
published recommendations today are contained in the AAPM’s
reports from its Task Groups 40 and 142 on comprehensive QA (44,
45). Consequently, the RPC judges the quality of an institution’s
QA program against the AAPM’s TG-40 and -142 recommenda-
tions. Significant differences with the AAPM recommendations are
found frequently, but in some cases, these are justified by the insti-
tution’s own procedures and measurements. More often, however,
the institution has overlooked some component of recommended
QA, or has allowed their program to lapse in some important
aspect. A list of common failures or lapses in QA programs found
by the RPC appears in Table 3 (8).
Table 2 | Some of the discrepancies detected during RPC dosimetry
review visits to 156 institutions in 2005–2011.
Errors regarding Number of institutions (%)
Inadequacy of QA program 115 (74)
Photon field-size dependence (small fields)* 62 (40)
Wedge transmission factor* 50 (32)
Off-axis factors, beam symmetry 46 (29)
Electron calibration* 27 (17)
Photon depth dose* 25 (16)
Electron depth dose* 18 (11)
Photon calibration* 13 (8)
The parameters indicated by “*” are considered significant dosimetry para-
meters that influence the calculation of patient treatment meter settings. Dur-
ing this 6-year period, 70% of the visited institutions received one or more
recommendations to address discrepancies in these dosimetry parameters.
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Table 3 | Common QA lapses and deficiencies found at institutions
during RPC visits.
QA records not available or maintained
Annual calibrations or monthly checks not performed timely
No record of comparison to clinical values on annual report
No record of comparison of daily and monthly checks against annual
“baseline” values
Physicist review of daily checks not documented
No record of corrective actions and repeat measurements
Check of electron beam energy not performed as required by applicable
regulations and recommendations
Output or field flatness constancy with gantry angle not checked during
annual calibration
OBSERVATIONS FROM REVIEWS OF PATIENT RECORDS
Quality assurance offices often participate in the QA review of the
treatment records of patients treated on protocols managed by
cooperative study groups. The QA office’s role can vary with the
trial, but in the RPC’s case, this role often incorporates an inde-
pendent recalculation of the patient dose, and a comparison with
both the dose stated by the institution and the dose required by
the protocol. The independent calculation is based on the treat-
ment parameters stated by the institution, such as field size and
MU setting, but utilizes the RPC’s data from the institution’s treat-
ment machines. If the RPC has conducted a dosimetry review visit
to the institution, the measured beam parameters are used for
calculation. If the RPC has not visited, the standard data (40) are
used together with measurements of machine calibration from the
RPC’s annual TLD audits.
Results from 5 years of the RPC’s reviews of charts were ana-
lyzed in preparation for submission of a grant renewal application
in 2010. The data were collected from 2004 to 2008 and included
1,506 patients for which doses were calculated at 8,448 points.
The discrepancies were divided into systematic errors, individual
errors, and transcription errors. To be identified as an error, the
patient dose had to disagree with the institution’s stated dose by
more than 5% for external beam treatment, and by more than
15% for brachytherapy treatments. Systematic errors were those
believed to affect all patients at an institution, who were treated
with a specific treatment machine or source, or for which a partic-
ular device such as a wedge, was used. Such errors were relatively
infrequent, but were found in 1% of the records reviewed. Individ-
ual errors were those believed to affect only the patient in question.
These errors occurred more frequently, about 11% of the time.
Transcription errors reflected cases in which the data reported to
the study group did not accurately reflect data recorded in the
treatment record. Such errors occurred surprisingly frequently;
about 27% of the time.
All together, 39% of the charts reviewed by the RPC contained
one or more of the errors described above. In each case, the error
was corrected by the RPC and reported to the study group so
that correct information could be used for evaluation of the clin-
ical trial. The results of these reviews were also reported to the
institutions promptly, to enable the institutions to take corrective
action. When errors affecting patient dose were detected, the RPC
contacted the institution to confirm that the records accurately
reflected the patient’s treatment, and that the RPC understood
the institution’s calculation procedures. When the errors were
confirmed, the RPC conveyed the details of its calculations and
investigated the reasons for the discrepancy.
RESULTS OF TREATMENT PLANNING BENCHMARK TESTS
For some trials, several QA offices have developed techniques to
credential institutions through the use of a treatment planning
exercise called a“benchmark case.” The purpose of the benchmark
case is to test whether an institution can meet one or more require-
ments specified in the trial, such as dose prescription, contouring,
etc. To comply, an institution must download a standardized CT
data set (or comparable imaging information) and generate a treat-
ment plan that complied with the requirements of the relevant
trial. The treatment plan must then be submitted digitally for eval-
uation. Evaluation generally consisted of review of target volume
contours and DVHs (60, 61). However, when used by the RPC,
an independent calculation of dose to the target was customarily
performed. When benchmark cases failed to meet the criteria, the
RPC contacted the institution, explained the discrepancies, and
worked with the institution to resolve them. The follow-up gen-
erally consisted of irradiation of an anthropomorphic phantom
as a more definitive end-to-end test of the treatment planning
capability.
RESULTS OF ANTHROPOMORPHIC PHANTOM REVIEWS
Several QA offices have reported the results of independent audits
with an anthropomorphic phantom. During the time period
2001–2011 the RPC mailed head-and-neck phantoms to 763 dis-
tinct institutions. The institutions were instructed to perform
imaging, develop a treatment plan using IMRT techniques, and
then deliver the treatment to the phantom. A total of 1,139
irradiations were analyzed. Of these, 929 irradiations or 82%
successfully met the irradiation criteria of 7% and 4 mm distance-
to-agreement (DTA). The passing rate has increased steadily since
the phantom’s introduction in 2001 from approximately 69% to a
current rate of 91% (3).
Had the dose criterion been reduced to 5%, only 69% of the
irradiations would have passed. Two hundred and ten irradia-
tions failed to meet the irradiation criteria; of these the majority
(74%) failed only the dose criterion. The remaining unsuccessful
irradiations failed the DTA criterion or both the dose and DTA
criteria. Some institutions have irradiated a phantom, particularly
the RPC’s head-and-neck phantom, multiple times because they
wanted to improve their initial irradiation results, test different
treatment planning system algorithms or test different treatment
delivery systems.
A study was performed comparing the results from the bench-
mark case used by the Quality Assurance Review Center as an
IMRT treatment planning capability exercise, to the RPC IMRT
H&N phantom irradiation results from the same group of 113
institutions was performed. All of the institutions passed the
IMRT benchmark case (planning study and self-reported IMRT
QA measurement) while 20 of these same institutions did not pass
the end-to-end independent phantom irradiation. The phantom
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audit is capable of detecting imaging, data transfer and delivery
errors that cannot be detected by the institution’s completion of
a benchmark case. In addition, each institution’s own IMRT QA
results of their IMRT benchmark plans passed their own QA crite-
ria. An independent end-to-end anthropomorphic QA audit such
as those used by the RPC are capable of detecting dosimetry errors
that might otherwise go undetected.
The most common TPSs used to plan the irradiations of the
phantom were the Phillips Pinnacle and Varian Eclipse systems.
The pass rates for these two TPSs were approximately 75 and
88%, respectively. The difference is believed to be due to diffi-
culties in modeling the penumbra at the ends of rounded MLC
leaves (62).
INCORPORATING NEW AND COMPLEX TECHNOLOGIES INTO
CLINICAL TRIALS
Clinical trials that are open to recruitment over a protracted period
typically struggle to keep pace with new technology as it is imple-
mented in the clinic. There needs to be a balance between ensuring
the new technology will not impact on the ability of the trial to
answer the trial question, but at the same time, it is important
that trials produce data using treatment techniques that are not
outdated. The CCTGs may try to anticipate upcoming develop-
ments, but it is often difficult to develop a QA and credentialing
program in a rapid time span due to limited access to equipment,
limited experience of the trial teams, and lack of published data
to provide the evidence to support the introduction of the new
technology (1, 29).
New trials that deliberately set-out to incorporate new technol-
ogy offer an ideal opportunity for medical physicists to exchange
knowledge and experience as the new technology is introduced
into the clinic. Credentialing programs are designed to assist cen-
ters to meet protocol requirements. The results of all studies
within a clinical trial remain anonymous, and a good creden-
tialing team will offer support to those centers that struggle to
meet the goals of the protocol. This in turn offers benefits to
patients who can be assured that the new technology has under-
gone peer review prior to clinical implementation. It is impor-
tant to note however, that it is the responsibility of the hospi-
tal staff to ensure patient safety, and participating in a clinical
trial credentialing program can support, but not take on that
role.
In designing a clinical trial that incorporates new technol-
ogy, the clinical trial management committee must first agree
on the level of support that it is able to offer radiotherapy cen-
ters. Trials running on a limited budget or with minimal support
may exclude centers without a significant amount of experience
in using the new technology so that only limited support is
required. This may introduce bias into the clinical trial results
as the results may only achievable in highly experienced cen-
ters. Ideally, a trial that permits a new technology should set
up a comprehensive credentialing program including site vis-
its, a detailed QA program, and set up a network for providing
support for centers with similar equipment such as the com-
prehensive QA program conducted during the introduction of
3DCRT in UK centers participating in the MRC RT01 trial (34,
63–65).
CONCLUSION
Clinical trials can be a powerful tool for demonstrating the effec-
tiveness of a clinical intervention or treatment. In radiation ther-
apy, clinical trials have proven the benefits (or lack thereof) of
specific fractionation regimens, advantages of combinations of
radiation with chemotherapeutic agents and radiation sensitizers,
and the potential of new modalities. However, the most compelling
trials are those in which the benefits of the proposed treatment
methodology are evaluated through multicenter Phase III ran-
domized trials. While such trials can potentially demonstrate the
ability of the community at large to deliver the treatment effectively
and thus reap the benefits, these trials also are more likely to suf-
fer from variations in treatment quality among the participating
institutions. A comprehensive QA program can define the range
of acceptable and unacceptable variations, detect, and correct the
causes of such variations, and document the frequency of varia-
tions. The ability of QA programs to reduce variations in treatment
delivery and improve the quality of clinical trials has been demon-
strated. For such QA programs to be effective, the clinical trials
cooperative groups as well as the participating institutions must
embrace them. Education in clinical trials QA should be offered
regularly at venues such as national and international professional
and scientific meetings, and at meetings of the cooperative groups
themselves.
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